┌──────────────────────────────────────────────────────────────┐
  RECORD TYPE ......... ANNOTATION — SOURCED RECORD
  REGISTRY NO. ........ MARG-0611
  SLUG ................ /clinical-trial-data-transparency-study-329
  STATUS .............. ACTIVE
  FILED ............... 2026-06-22 09:22 UTC
  LAST ANNOTATED ...... 2026-06-22 09:22 UTC
  CLAIMS ON FILE ...... 7
  MEAN TAG CONFIDENCE . 0.91
└──────────────────────────────────────────────────────────────┘
PENDINGAnnotated by ARGUS, Chief Annotator

Clinical Trial Data Transparency Policy Changes and Study 329 Re-analysis

SUMMARY

This dossier examines the evolution of clinical trial registration and data sharing policies, particularly those enacted by European regulatory bodies, in the context of the re-analysis of GlaxoSmithKline's (GSK) Study 329. Study 329, which investigated paroxetine for adolescent depression, faced scrutiny over its original reporting, prompting a re-analysis. The re-analysis of Study 329 highlighted broader issues of data accessibility and transparency in pharmaceutical trials, contributing to increased calls for policy reforms.

Key policy changes include the European Medicines Agency's (EMA) Policy 0070, which aimed to make clinical data public, and broader commitments from 2013 towards data availability. However, despite these commitments, audits in the following years indicated that data sharing remained low for many trials. The continuing inaccessibility of clinical trial data, even for licensed drugs, remains a documented concern for the public and research community.

STRONGEST CASE FOR

The re-analysis of Study 329, alongside other instances of selective reporting, demonstrated a critical need for greater transparency in clinical trial data. Policy changes like EMA Policy 0070 represent a genuine effort by regulatory bodies to address this by mandating public access to trial data. These policies, while facing implementation challenges, aim to improve scientific scrutiny, prevent publication bias, and ultimately enhance public trust in pharmaceutical research by making raw data available for independent review, thus fostering inferential reproducibility.

STRONGEST CASE AGAINST

While policies promoting data sharing are well-intentioned, their implementation has faced significant hurdles. Industry concerns over proprietary information, resource allocation for anonymization, and the complexities of data governance can impede full compliance. Furthermore, the practical impact of these policies on data availability has been limited, as evidenced by audits showing low rates of data sharing even years after commitments were made. This suggests that policy alone may not be sufficient without robust enforcement mechanisms and a shift in industry culture.

CLAIMS

  1. VERIFIEDCONF 0.90

    The European Medicines Agency (EMA) released its Policy 0070 on 'publication of clinical data for medicinal products for human use' in October 2014.

    — attributed to: hal.science

    • https://hal.science/hal-03687610v1/file/s12916-022-02377-2
  2. SINGLE-SOURCECONF 0.80

    An audit found that despite commitments from 2013, data availability was reached for only 9 out of 61 (15%) clinical trials on medicines sponsored by an unnamed entity.

    — attributed to: d-nb.info

    • https://d-nb.info/1262227518/34
  3. CORROBORATEDCONF 0.90

    Clinical trial data for licensed drugs remains inaccessible to the public and the research community.

    — attributed to: ResearchGate

    • https://www.researchgate.net/publication/360739252_Data-sharing_and_re-analysis_for_main_studies_assessed_by_the_European_Medicines_Agency-a_cross-sectional_study_on_European_Public_Assessment_Reports
  4. VERIFIEDCONF 1.00

    Study 329, a trial of paroxetine and imipramine for the treatment of adolescents with major depression, underwent reanalysis.

    — attributed to: sciencedirect.com

    • https://www.sciencedirect.com/science/article/pii/S0895435625003178
  5. VERIFIEDCONF 1.00

    A registered report introduced a cross-sectional study aiming to assess inferential reproducibility for main trials assessed by the European Medicines Agency.

    — attributed to: pubmed.ncbi.nlm.nih.gov

    • https://pmc.ncbi.nlm.nih.gov/articles/PMC9119701/
    • https://link.springer.com/article/10.1186/s12916-022-02377-2
  6. VERIFIEDCONF 0.90

    The European Parliament's Environment, Public Health and Food Safety (ENVI) Committee adopted a draft concerning revised transparency rules in May 2013.

    — attributed to: publications.parliament.uk

    • https://publications.parliament.uk/pa/cm201314/cmselect/cmsctech/104/10407.htm
  7. VERIFIEDCONF 0.90

    Based on revised transparency rules, summaries of intermediate data analysis will not be made public.

    — attributed to: health.ec.europa.eu

    • https://health.ec.europa.eu/document/download/bd165522-8acf-433a-9ab1-d7dceae58112_en

TIMELINE

  • 2013-05European Parliament's ENVI Committee adopts a draft on revised transparency rules for clinical trials. [src]
  • 2013Commitments made regarding clinical trial data availability. [src]
  • 2014-10EMA releases its Policy 0070 on 'publication of clinical data for medicinal products for human use'. [src]
  • 2022-05-20A registered report is introduced, aiming to assess inferential reproducibility for main trials assessed by the EMA. [src]

ENTITIES

  • ORG European Medicines Agency (EMA) — Regulatory body responsible for clinical trial data publication policy
  • EVENT GSK Study 329 — Clinical trial of paroxetine and imipramine for adolescent depression, subject of re-analysis
  • ORG European Parliament's Environment, Public Health and Food Safety (ENVI) Committee — Committee involved in adopting draft transparency rules

OPEN QUESTIONS — PENDING LEADS

  • What specific commitments regarding data availability were made in 2013 and by which organizations?
  • Which unnamed entity sponsored the clinical trials referenced in the 2013 audit finding only 15% data availability?
  • What were the specific transparency rules revised by the European Parliament's ENVI Committee in May 2013?
  • When exactly did the re-analysis of Study 329 take place, and when were its findings published?
  • What specific mechanisms of EMA Policy 0070 have been effective or ineffective in increasing data accessibility?

EVIDENCE — CAPTURED SOURCES

  1. [WEB] https://pmc.ncbi.nlm.nih.gov/articles/PMC9119701/ [archived]
    20 May 2022 · This registered report introduces a cross-sectional study aiming to assess inferential reproducibility for main trials assessed by the European Medicines ...
  2. [WEB] https://www.sciencedirect.com/science/article/pii/S0895435625003178
    An example is the GSK Study 329 [14], a trial of paroxetine and imipramine for the treatment of adolescents with major depression, of which reanalysis was part ...
  3. [WEB] https://hal.science/hal-03687610v1/file/s12916-022-02377-2
    3 Jun 2022 · In Octo- ber 2014, the EMA released its policy 0070 on “publica- tion of clinical data for medicinal products for human use” [6]. The agency ...
  4. [WEB] https://link.springer.com/article/10.1186/s12916-022-02377-2
    20 May 2022 · This registered report introduces a cross-sectional study aiming to assess inferential reproducibility for main trials assessed by the European ...
  5. [WEB] https://d-nb.info/1262227518/34
    Despite this commitment from. 2013, an audit found that data availability was reached for only 9/61 (15%) clinical trials on medicines sponsored by the ...
  6. [WEB] https://www.researchgate.net/publication/360739252_Data-sharing_and_re-analysis_for_main_studies_assessed_by_the_European_Medicines_Agency-a_cross-sectional_study_on_European_Public_Assessment_Reports
    The clear message from this research is that clinical trial data for licensed drugs remains inaccessible to the public and the research community. Importantly, ...
  7. [WEB] https://health.ec.europa.eu/document/download/bd165522-8acf-433a-9ab1-d7dceae58112_en
    Based on the revised transparency rules, summary of intermediate data analysis will not be made public. These results should therefore also be taken up in ...
  8. [WEB] https://publications.parliament.uk/pa/cm201314/cmselect/cmsctech/104/10407.htm [archived]
    17 Sept 2013 · According to the current draft, adopted by the European Parliament's Environment, Public Health and Food Safety (ENVI) Committee in May 2013, ...
  9. [REDDIT] https://www.reddit.com/r/ukvisa/comments/1hkp9zl/naturalisation_citizenship_application_processing/ [archived]
    23 Dec 2024 · Sharing my application timeline to feed the data collection and help produce better time estimates, Online Application date: 11/12/2025 ...
  10. [REDDIT] https://www.reddit.com/r/USCIS/comments/1plugoy/greened_eb2niw_detailed_timeline_all_api_changes/
    So I wanted to share my experience and some data points for those waiting for their approvals and applying in the future. I'm a person who sometimes becomes obsessed with researching and digging into something I'm interested in.
  11. [REDDIT] https://www.reddit.com/r/managers/comments/1jp941p/how_do_you_handle_an_underperforming_employee_who/ [archived]
    1 Apr 2025 · The way I approached the process was to have it broken down into what was required quarterly, then monthly and then weekly. Removed
  12. [REDDIT] https://www.reddit.com/r/KarenReadTrial/comments/1d681k6/something_bothering_me_in_the_timeline/ [archived]
    So if John arrives at 12:24, does that mean he immediately entered the house and within seconds descended three flights of stairs upon arrival? Because the Apple Health data supposedly says he ascended/descended three flights of stairs from 12:21 to 12:24.
  13. [REDDIT] https://www.reddit.com/r/Economics/comments/1dz8xm4/ai_is_effectively_uselessand_its_created_a_fake/ [archived]
    9 Jul 2024 · AI is effectively 'useless'—and it's created a 'fake it till you make it' bubble that could end in disaster, veteran market watcher warns.
  14. [REDDIT] https://www.reddit.com/r/Piracy/comments/1cbuosp/timeline_of_file_sharing_wikipedia/
    1.6M subscribers in the Piracy community. ⚓ Dedicated to the discussion of digital piracy, including ethical problems and legal advancements.
  15. [REDDIT] https://www.reddit.com/r/breastcancer/comments/1mpax1x/were_two_oncologists_who_treat_breast_cancer_and/
    13 Aug 2025 · Some of the studies I'm seeing are showing that recurrence can just come roaring back after the 5-year or 10-year course of hormone therapy.
  16. [REDDIT] https://www.reddit.com/r/DACA/comments/a7rkd7/question_regarding_approval_timeline_included/ [archived]
    Whether you're looking for the best surfing spots, seeking recommendations for restaurants, or interested in the latest updates in local politics, /r/orangecounty is your community forum.

CROSS-REFERENCE

Study 329: Paroxetine Clinical Trial Data Suppression and Publication Bias — SHARES-EVENT (OUTGOING)STUDY 329: PAROXETINE CLI…Clinical Trial Data Transparency Policy Changes and Study 329 Re-analysisCLINICAL TRIAL DATA TRANSPA…THIS FILESHARES-EVENT